TriSalus Life Sciences, Inc.
NASDAQ:TLSIMedical - Devices
+$0.02 today
- Market cap
- $151.16M
- Beta
- 0.49
- P/E (TTM)
- -7.4
- EPS (TTM)
- -$0.53
Volume 0.40M
Average 0.38M
TLSI Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
TriSalus Life Sciences, Inc.NASDAQ: TLSI
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization declines year over year
Q1 FY2026 depreciation & amortization of $135K fell 21.5% year over year, behind the -20.5% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 7.1% from the prior quarter. Over 3 fiscal years it compounded at +14.8% a year.
Context
- Depreciation & amortization amounted to 1.4% of revenue in FY2025, down 1.1 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth recovers from -21.5% toward the trailing-twelve-month pace of -20.5%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 626K USD
- Year-over-year change
- -15.9%
- 4-year CAGR
- +7.8%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 626K | -15.9% |
| FY2024 | 2024-12-31 | 744K | +8.8% |
| FY2023 | 2023-12-31 | 684K | +65.2% |
| FY2022 | 2022-12-31 | 414K | -10.8% |
| FY2021 | 2021-12-31 | 464K | — |
Depreciation & Amortization vs competitors
How TLSI compares with its peers on the latest reported figures
- TLSI's LTM Mar 2026 depreciation & amortization of $589K is the 10th highest of the 11 companies compared; the peer median is $3.47M.
- Its year-over-year change of -20.5% is the 9th highest of 11, against a peer median of +10.2%.
- Depreciation & amortization amounts to 1.3% of revenue for TLSI, versus a peer median of 10.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $4.56M | +11.6% | +9.7% | 7.9% | |
| LTM Mar 2026 | $4.48M | -11.7% | +24.0% | 13.9% | |
| LTM Mar 2026 | $3.97M | +79.9% | -20.6% | 3.5% | |
| LTM Mar 2026 | $3.65M | +35.4% | +111.4% | 589.8% | |
| LTM Mar 2026 | $3.3M | +36.1% | +28.1% | 2.2% | |
AVRAnteris Technologies Global Corp. | LTM Mar 2026 | $1.69M | +8.7% | +29.0% | 91.1% |
| LTM Mar 2026 | $1.61M | +16.3% | +19.7% | 54.5% | |
| LTM Mar 2026 | $627K | -41.1% | -39.6% | 0.6% | |
| LTM Mar 2026 | $589K | -20.5% | +14.8% | 1.3% | |
| LTM Mar 2026 | $499.7K | -57.0% | -29.2% | 2.6% | |
| Peer median (excluding TLSI) | $3.47M | +10.2% | +14.7% | 10.9% | |
Competitors are the stored peer set for TLSI. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 8.4M | 12.4M | 18.51M | 29.43M | 45.15M |
| Cost of Revenue | 1.19M | 2.26M | 2.61M | 4.1M | 6.97M |
| Gross Profit | 7.21M | 10.14M | 15.91M | 25.33M | 38.19M |
| Gross Margin | 85.8% | 81.8% | 85.9% | 86.1% | 84.6% |
| Research & Development | 14.22M | 21.36M | 29.84M | 17.69M | 14.97M |
| Selling, General & Admin | 17.02M | 25.22M | 40.55M | 43.81M | 50.17M |
| Operating Expenses | 31.24M | 46.58M | 70.38M | 61.49M | 65.13M |
| Depreciation & Amortization | 464K | 414K | 684K | 744K | 626K |
| EBITDA | (26.62M) | (46.76M) | (58.65M) | (32.39M) | (33.05M) |
| EBITDA Margin | -316.8% | -377.2% | -316.9% | -110.0% | -73.2% |
| Operating Income | (24.03M) | (36.44M) | (54.48M) | (36.17M) | (26.95M) |
| Operating Margin | -286.1% | -293.9% | -294.3% | -122.9% | -59.7% |
| Interest Income | 0 | 180K | 431K | 404K | 555K |
| Interest Expense | 1.76M | 1K | 16K | 3.09M | 5.54M |
| Other Income / Expenses | (4.81M) | (10.74M) | (4.88M) | 6.13M | (12.27M) |
| Income Before Tax | (28.84M) | (47.18M) | (59.35M) | (30.04M) | (39.22M) |
| Pre-Tax Margin | -343.3% | -380.5% | -320.6% | -102.1% | -86.9% |
| Income Tax Expense | 3K | 9K | 9K | 6K | 7K |
| Net Income | (28.85M) | (47.19M) | (59.36M) | (33.23M) | (39.23M) |
| Net Margin | -343.4% | -380.6% | -320.7% | -112.9% | -86.9% |
| EPS (Basic) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| EPS (Diluted) | (0.92) | (1.59) | (2.23) | (1.25) | (1.84) |
| Weighted Avg Shares | 31.25M | 29.61M | 26.47M | 26.5M | 49.19M |
| Weighted Avg Shares (Diluted) | 31.25M | 29.61M | 26.47M | 26.5M | 37.9M |
TriSalus Life Sciences, Inc.
NASDAQ:TLSI
Intrinsic Alpha fair value
Locked
Current Price
$2.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.